See more : NAURA Technology Group Co., Ltd. (002371.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of BELLUS Health Inc. (BLU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BELLUS Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- AirTrip Corp. (6191.T) Income Statement Analysis – Financial Results
- Regency Silver Corp. (RSMXF) Income Statement Analysis – Financial Results
- Pilbara Minerals Limited (PILBF) Income Statement Analysis – Financial Results
- Wuxi Huadong Heavy Machinery Co., Ltd. (002685.SZ) Income Statement Analysis – Financial Results
- Inner Mongolia MengDian HuaNeng Thermal Power Corporation Limited (600863.SS) Income Statement Analysis – Financial Results
BELLUS Health Inc. (BLU)
About BELLUS Health Inc.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 16.00K | 16.00K | 15.00K | 26.79K | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.12M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.74M | 2.91M | 109.80K | 0.00 | 2.25M | 5.52M | 118.83K |
Cost of Revenue | 3.51B | 2.22B | 1.43B | 994.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -137.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 693.62K | -470.29K | 0.00 | 0.00 | -1.16M | 0.00 | 0.00 |
Gross Profit | -3.51B | -2.22B | -1.43B | -994.49M | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.26M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.05M | 3.38M | 109.80K | 0.00 | 3.41M | 5.52M | 118.83K |
Gross Profit Ratio | -21,967,104.08% | -13,887,173.94% | -9,536,119.55% | -3,711,740.75% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 106.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.71% | 116.14% | 100.00% | 0.00% | 151.65% | 100.00% | 100.00% |
Research & Development | 58.89M | 59.79M | 23.73M | 20.00M | 5.28M | 2.87M | 1.13M | 931.76K | 1.46M | 1.19M | 998.16K | 1.29M | 7.05M | 10.04M | 23.60M | 55.45M | 49.54M | 40.61M | 24.42M | 5.71M | 8.03M | 6.56M | 3.19M |
General & Administrative | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 0.00 | 7.69M | 8.57M | 11.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 611.90K | 3.71M | 6.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 3.47M | 8.30M | 12.28M | 18.45M | 15.17M | 14.67M | 23.25M | 18.29M | 5.75M | 2.44M | 396.43K | 1.02M |
Other Expenses | -491.00K | -754.00K | -507.00K | -543.53K | -479.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 653.38K | 5.34M | -5.05M | 13.11M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 65.73M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
Cost & Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 66.42M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
Interest Income | 5.08M | 233.00K | 1.05M | 1.16M | 265.78K | 63.62K | 74.40K | 104.49K | 170.56K | 189.71K | 137.71K | 105.78K | 151.98K | 102.00K | 907.00K | 0.00 | 2.36M | 2.08M | 0.00 | 520.42K | 1.14M | 0.00 | 0.00 |
Interest Expense | 78.00K | 55.00K | 39.00K | 22.97K | 3.67K | 8.75K | 8.18K | 7.93K | 89.59K | 133.36K | 220.14K | 333.01K | 526.92K | 324.00K | 271.00K | 0.00 | 151.45K | 461.68K | 0.00 | 46.37K | 232.00K | 0.00 | 0.00 |
Depreciation & Amortization | 5.12M | 426.00K | 1.22M | 1.28M | 325.25K | 63.62K | 49.10K | 104.49K | 345.43K | 658.36K | -17.49M | 45.05K | 1.47M | 693.00K | 1.88M | 399.00K | 335.82K | 2.60M | 1.70M | 497.67K | 585.56K | 278.82K | 224.15K |
EBITDA | -72.76M | -72.86M | -31.72M | -24.82M | -6.95M | -4.46M | -1.51M | 28.10K | -1.78M | -2.43M | -21.12M | -1.71M | -13.22M | -7.21M | -46.07M | -66.97M | -62.16M | -60.94M | -42.60M | -11.46M | -8.22M | -1.44M | -4.09M |
EBITDA Ratio | -454,768.75% | -455,362.50% | -211,453.33% | -92,637.22% | -27,038.13% | -3,396.99% | -107.29% | 0.97% | -87.04% | -114.72% | -914.36% | -56.95% | -549.21% | 6,215.52% | -7,888.36% | -4,443.66% | -2,266.69% | -2,091.58% | -38,800.14% | 0.00% | -365.10% | -26.07% | -3,440.36% |
Operating Income | -77.88M | -73.28M | -32.94M | -26.10M | -7.27M | -4.52M | -1.56M | -76.39K | -2.13M | -3.09M | -3.64M | -1.76M | -14.69M | -21.12M | -45.66M | -68.66M | -63.68M | -63.69M | -44.30M | -11.95M | -8.81M | -1.72M | -4.31M |
Operating Income Ratio | -486,768.75% | -458,025.00% | -219,613.33% | -97,431.66% | -28,303.89% | -3,445.47% | -110.78% | -2.63% | -103.91% | -145.79% | -157.40% | -58.45% | -610.09% | 18,204.31% | -7,817.64% | -4,555.81% | -2,321.87% | -2,185.81% | -40,350.15% | 0.00% | -391.10% | -31.13% | -3,629.00% |
Total Other Income/Expenses | 1.86M | 1.86M | 1.19M | -280.19K | 603.51K | 3.08M | -86.30K | 348.78K | 389.37K | 2.18M | -9.60M | 5.34M | -5.05M | 12.89M | -2.57M | -12.42M | -999.45K | 1.38M | 714.67K | -1.35M | 74.51K | 0.00 | 316.65K |
Income Before Tax | -76.02M | -71.42M | -31.76M | -26.39M | -6.67M | -1.44M | -1.65M | 272.40K | -1.74M | -911.93K | -13.24M | 3.58M | -19.73M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -13.30M | -8.73M | 0.00 | -4.00M |
Income Before Tax Ratio | -475,125.00% | -446,393.75% | -211,713.33% | -98,477.40% | -25,955.23% | -1,098.79% | -116.90% | 9.39% | -84.89% | -43.04% | -573.11% | 119.24% | -819.68% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -387.79% | 0.00% | -3,362.52% |
Income Tax Expense | 60.00K | -199.00K | 39.00K | 22.97K | -607.18K | 48.51K | 11.16K | -19.46K | -42.21K | -617.97K | 18.44M | 227.23K | 374.94K | 13.44M | 1.32M | -1.94M | -1.50M | -2.04M | -626.83K | -365.56K | 152.98K | 58.14K | -227.53K |
Net Income | -76.08M | -71.22M | -31.80M | -26.41M | -6.06M | -1.49M | -1.61M | 145.57K | -1.66M | -818.96K | -13.32M | 3.35M | -20.11M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -12.93M | -8.89M | -1.78M | -3.77M |
Net Income Ratio | -475,500.00% | -445,150.00% | -211,973.33% | -98,563.12% | -23,592.29% | -1,135.76% | -114.05% | 5.02% | -81.27% | -38.65% | -576.81% | 111.68% | -835.26% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -394.58% | -32.18% | -3,171.04% |
EPS | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | 1.38 | -10.28 | -6.34 | -105.15 | -198.86 | -181.01 | -196.26 | -156.38 | -52.10 | -53.29 | -11.00 | -32.16 |
EPS Diluted | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | -0.67 | -10.28 | -6.30 | -105.15 | -198.86 | -181.01 | -187.15 | -137.04 | -44.64 | -49.86 | -11.00 | -32.16 |
Weighted Avg Shares Out | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 2.47M | 1.96M | 1.30M | 458.62K | 407.69K | 357.31K | 317.48K | 278.73K | 248.27K | 166.73K | 161.45K | 117.17K |
Weighted Avg Shares Out (Dil) | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 6.04M | 1.96M | 1.31M | 458.62K | 407.69K | 357.31K | 332.93K | 318.06K | 289.73K | 178.21K | 161.45K | 117.17K |
Bellus Health shareholders say yes to US$2B GSK takeover
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
Alliance Entertainment Reports Third Quarter and Nine Month Fiscal 2023 Financial Results
BELLUS Santé inc. convoque une assemblée extraordinaire des actionnaires concernant l’acquisition de la société par GSK
BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
BELLUS Santé annonce ses résultats financiers et faits saillants pour le premier trimestre de 2023
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
Tommy Hilfiger, Mercedes-AMG PETRONAS Formula One Team e Awake NY lanciano una collaborazione al Grand Prix di Miami
Crackle Connex Showcases Its Unique Advertising and Media Offering at IAB Newfronts
Source: https://incomestatements.info
Category: Stock Reports